The future of the global polyvalent streptococcus pneumococcal vaccine market looks promising with opportunities in the hospital, community clinics, and public health agencies markets.
- Within the type category, 13-valent is expected to witness the highest growth over the forecast period due to it offers broader protection against a greater number of pneumococcal serotypes.
- Within the application category, hospital is expected to witness the highest growth due to specialized care, emergency treatment, and advanced diagnostic services.
- In terms of regions, North America is expected to witness the highest growth over the forecast period due to significant investment in medical research and development.
Emerging Trends in Polyvalent Streptococcus Pneumococcal Vaccine Market
Polyvalent streptococcus pneumococcal vaccine market is projected to progress from infant-focused to comprehensive protection for the entire specified group, spans from 2025 to 2027. Governments are rebalancing their schedules, and manufacturers are increasing the serotype span, and payers are juggling the value of conjugate vaccines with the disease burden. Lucintel’s market opinion coincides with the conviction that the growing adult population and the evolving adult immunization programs spring positive demand.- Serotype Expands: In June 2024, WHO prequalified PCV21, while Pfizer’s CAPVAXIVE covers 21 serotypes for adults, creating a positive case for a broader scope of protection against disease. Within three to five years, manufacturers are likely to intensify competition based on serotype coverage as the serotype replacement phenomenon will update and revise the existing schedules.
- Adult Vaccination: U.S. CDC’s announced pneumococcal vaccination for adults aged 50 and older for 2025, lowering the routine age limit from 65, this also is going to create positive demand within the adult vaccination programs. The growing adult population and chronic conditions will increase the invasive disease risk.
- Product Premiumization: Higher valency conjugate vaccines have created interest market wide, due to broader coverage and established immunogenicity. GSK’s 2024 premium respiratory vaccines with high valency Arexvy illustrates payer’s value for premium vaccines. The premium vaccines create a balance between pricing and outcomes, which will determine market accessibility through 2027.
- Regional Supply Diversification: UNICEF’s 2024 pneumococcal vaccine procurement reached 170 million doses, and illustrates the continued dependence on large public tenders. Governments are seeking alternate suppliers and are interested in creating local manufacturing, which will influence the outcome of the contracts, the balance, and the supply of vaccines in the upcoming period.
- Adult Combination Innovation: Progress in pipeline development is starting to join pneumococcal vaccination with broader respiratory prevention. Pfizer’s 2025 Respiratory Portfolio presentation focuses on the older adult population and indicates lifecycle expansion for this group. This focus should initiate studies on co-administration and campaigns that incorporate the combined elements to improve vaccination coverage for older adults who have limited vaccination coverage due to fragmented appointment scheduling.
Recent Developments in the Polyvalent Streptococcus Pneumococcal Vaccine Market
The polyvalent streptococcus pneumococcal vaccine market is growing throughout 2025-2027, as manufacturers look beyond the established PCV13 and PCV20 vaccines. Lucintel is anticipating a shift in focus towards larger segmented vaccines that simplify the schedule and provide a greater evidence-based approach for both pediatrics and older adult populations.- Expanded Valency Launches: Merck received approval for CAPVAXIVE® in the U.S. in June 2024, covering 21 serotypes and furthering the push beyond PCV20. Health systems will begin looking for new protection against invasive disease due to broadened coverage.
- Late Stage Pipeline: Positive topline results for phase III of VAX-31 from Vaxcyte’s Vax-31 announced in June 2026, supported an adult valency vaccine with 31 target serotypes. In the next three to five years, higher valency could drive innovative competition and new pricing for current pneumococcal products.
- Pediatric Program Expansion: Pfizer began higher-valent pneumococcal product evaluations in a pediatrics study in 2025, adding to its Prevnar 20. Established brands gain a significant advantage in the long-term market due to national pediatric schedules of vaccination.
- Public Program Approvals: The pneumococcal conjugate vaccine supply chain grew in India, a primary continental supplier, in 2025 due to the Indian government’s inclusion in its national primary health care program. Local production will fulfill market demand for growing immunization programs.
- Manufacturing Scale-up: Serum Institute of India increased pneumococcal vaccine production during 2025 to fulfill domestic and international requirements. This production increase will lessen their reliance on a few major global manufacturers and will help provide more affordable polyvalent product.
Strategic Growth Opportunities in the Polyvalent Streptococcus Pneumococcal Vaccine Market
The polyvalent streptococcus pneumococcal vaccine market will begin a lengthy sales cycle in 2024-2026 due to adult market expansion. Mixed with concerns for serotype replacement, antimicrobial resistance, and buying pressure. There are new opportunities beyond infant immunization with remaining protection gaps and obstacles to vaccination distribution.- Adult Immunization: Vaccine sales can increase to older adults (50 +) with additional chronic conditions, since they are also at risk. In January 2025, the U.S. CDC recommended routine vaccination of pneumococcal vaccination for adults aged 50-64. This group will offer a continual demand as the vaccination is implemented in their primary care health services.
- Higher Valency Premium Products: Due to constrained budgets, a higher valued, more comprehensive vaccine will create a competitive advantage against a vaccine with a narrower time frame protection against invasive disease. In March 2025, Pfizer released CAPVAXIVE, a vaccine against 21 serotypes, in the adult market. In the next 3-5 years, hospitals and national programs will favor this vaccine.
- Pediatric Private Market: Some supply lines can be created by private pediatric clinics in markets where public supply schedules do not fully accommodate targeted populations. In February 2025, the WHO cited that 154 nations had introduced pneumococcal conjugate vaccines. Private clinics will be the only option for delayed, catch-up vaccinations and vaccinations for traveling or overseas workers.
- Emerging-market Manufacturing: Regional fill-finish and technology-transfer partnerships can reduce procurement costs and improve supply security. In May 2025, Gavi’s pneumococcal vaccine support covered 57 lower income countries. Local production will become more attractive as governments seek shorter supply chains and greater bargaining power.
- Combination and Thermos Formulated Products: Products requiring fewer visits or less demanding cold-chain conditions can reach underserved populations. In April 2025, WHO set 2-8°C as the standard temperature requirement for licensed pneumococcal conjugate vaccines. Formulation advances will influence tenders by reducing delivery losses and administration costs.
Polyvalent Streptococcus Pneumococcal Vaccine Market Drivers and Challenges
The polyvalent streptococcus pneumococcal vaccine market is dominated by evolving public health needs, changing regulations, and advanced technology. Increasing awareness towards pneumococcal diseases drives demand, and the wider inclusion of adult vaccination programs generates market opportunities. Complexities in manufacturing, competitive pricing, and constrained supply and demand are among the prominent challenges. According to Lucintel, aging, innovation in pediatric vaccines, and government purchases are the most significant of the other factors. Over the forthcoming years, the biggest challenge facing the market will be balancing the demands for broader protection, more reasonable pricing, and sufficient evidence to support the safety and efficacy of delivery of vaccines to a global market.The factors responsible for driving this market include:
- Increasing Immunization Demand: Driving demand are the burdens of urbanization, chronic conditions, and persistent childhood infections coupled with the aging of the population. In June 2025, the World Health Organization (WHO) continued to publish data indicating that pneumococcal disease is a vaccine preventable illness which continues to cause annual infection for millions of children. Knowledge of this will drive the market for the next 3 to 5 years, while governments continue to protect older and high-risk, adult and adult immunocompromised, populations.
- Product Innovation: Innovation in this space is achieving greater serotype replacement by addressing the need for higher valency conjugate vaccines. In October 2024, the U.S. Food and Drug Administration approved the use of a 21 valent pneumococcal vaccine for adults. Competition will continue through 2029 with the goal of achieving a more favorable pricing position through enhanced protection against emerging serotypes and a shortened dosing schedule.
- Government Immunization Programs: Stable demand for multi-valent vaccines exists due to national vaccination schedules, public buying, and international health initiatives. January 2025 saw continued funding for Gavi’s routine immunization, focused on providing the pneumococcal vaccine for unprecedented low-income countries where the childhood vaccination drive is a public health concern. For the next three to five years, market size will depend on government buying. This will then dictate purchasing tenders, vaccine preference, reimbursement, and the overall adoption rate in vulnerable areas.
- Increase in Adult Immunization: Greater Awareness around pneumococcal risk factors for older adults and adults with diabetes and cardiovascular disease is expanding the patient pool for pneumococcal vaccination. In May 2025, numerous national health systems began systematic immunization drives for adults over 50. This campaign is anticipated to drive increased market demand for pneumococcal vaccines through 2029, as even more adult vaccination clinics and pharmacies begin offering the vaccination.
- Expansion of Manufacturing and Distribution: Vaccine wastage will come down while increasing access, thanks to optimization of manufacturing and distribution. In March 2025, global immunization programs deployed innovative temperature-monitoring systems throughout the supply chain for vaccines that need to be stored at 2 to 8 degrees Celsius. This will increase market stability over the next three to five years due to improved delivery, lower logistics costs, and ability for manufacturers to accept larger tenders due to improved access to previously unserved or remote areas.
The challenges facing this market include:
- High Production Costs: The manufacture of conjugate vaccines requires substantial antigen preparation, conjugation of protein carriers, quality checks, and specialized facilities. In August 2025, public vaccine tenders published by a number of emerging markets adopted price-based procurement, creating a challenge for products that require multiple production stages and cold-chain maintenance. In the next three to five years, this challenge will impact the market by affecting affordability, decreasing the number of suppliers, and making gradual improvement in the scale of production, the transfer of manufacturing technology and the improvement of manufacturing efficiencies to offer better access.
- Regulatory and Clinical Complexity: New polyvalent vaccines must show protection against multiple serotypes across different populations of various age groups. In February 2025, regulatory agencies continued to request extensive comparative data as a basis for approving extended-valency products, which typically involve large number of study subjects. This challenge will affect the market until 2029 by increasing the cost of research, prolonging the research, and increasing the uncertainty of regulatory approvals, the extension of product labels, the recommendation of booster vaccines, and the analysis of the efficacy of the product in the field.
- Unequal Global Access and Supply Risks: There are constraints of low and middle-income countries caused by limited budgets, procurement delays, and poor installation of health services that are dependent on a small number of suppliers. In September 2025, the international planning of immunization continued to address the supply requirements of more than one hundred countries participating in coordinated vaccine programs. This challenge will affect the market in the next three to five years by causing a regional disparity and increased vulnerability of production disruptions, increasing the effort of governments to diversify suppliers, establish stockpiles, and promote local production.
List of Polyvalent Streptococcus Pneumococcal Vaccine Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies polyvalent streptococcus pneumococcal vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the polyvalent streptococcus pneumococcal vaccine market companies profiled in this report include:
- GlaxoSmithKline
- Merck
- Panacea Biotec
- Pfizer
- Pnuvax Incorporated
- Serum Institute
- Shinogi
- Shenzhen Kangtai Biological Products
- SK Bioscience
- Walvax Biotechnology
Polyvalent Streptococcus Pneumococcal Vaccine Market by Segment
The study includes a forecast for the global polyvalent streptococcus pneumococcal vaccine market by type, application, and region.Type [Value ($B) from 2019 to 2035]:
- 9-Valent
- 13-Valent
- 23-Valent
- Others
Application [Value ($B) from 2019 to 2035]:
- Hospital
- Community Clinics
- Public Health Agencies
- Others
Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Polyvalent Streptococcus Pneumococcal Vaccine Market
The polyvalent streptococcus pneumococcal vaccine market will restructure with expanded adult vaccination schedules, higher-valency products and local production. During 2025-2027, market share will be under the influence of procurement policies and production investments more than clinical differentiation. According to Lucintel’s market assessment, the level of execution at the country level will continue to determine the market leaders.- United States: Adult schedule expansion According to the CDC’s 2025 adult immunization schedule, pneumococcal vaccination for adults aged 50 and above, and at-risk adults and groups where products covering 21 serotypes are available, are included. This policy will generate a demand for higher-valency conjugate vaccines, and will encourage manufacturers to expand their hospital and pharmacy investments for the next 3-5 years.
- China: Domestic supply development The NMPA approved CanSino’s 13-valent pneumococcal conjugate vaccine for children in 2024. China's 2025 procurement continued to favor local vaccines. The addition of domestic production will provide improved supply and greater price competition for the next 3-5 years.
- Germany: EU regulatory integration German’s integration of the expanded EU vaccine procurement and health security framework during 2025, was undertaken concurrently with STIKO recommendations for adult pneumococcal vaccination for defined risk groups. The blending of aligned purchasing and recommendations will influence contracting practices within the next 3-5 years.
- India: The Serum Institute manufactures Pneumosil, a WHO prequalified 10-valent vaccine. According to the public records, the company is capable of manufacturing 100 million doses annually (by 2025). Scale-based domestic production is likely to sustain the government’s vaccination program and enable exports to the region in the next 3 to 5 years.
- Japan: Japan (2025) continued to utilize the government-funded pneumococcal vaccinations for adults 65 and older as well as adults at risk who were earlier unvaccinated, while the approval of Pfizer’s 20 valent C-vaccine was allowed for sale in 2024. Increasing market availability of products may influence coverage, prescribing practices and manufacturing activities within the next 3 to 5 years.
Features of the Global Polyvalent Streptococcus Pneumococcal Vaccine Market
- Market Size Estimates: polyvalent streptococcus pneumococcal vaccine market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2025 to 2031) by various segments and regions.
- Segmentation Analysis: polyvalent streptococcus pneumococcal vaccine market size by type, application, and region in terms of value ($B).
- Regional Analysis: polyvalent streptococcus pneumococcal vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the polyvalent streptococcus pneumococcal vaccine market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the polyvalent streptococcus pneumococcal vaccine market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the polyvalent streptococcus pneumococcal vaccine market by type (9-valent, 13-valent, 23-valent, and others), application (hospital, community clinics, public health agencies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- GlaxoSmithKline
- Merck
- Panacea Biotec
- Pfizer
- Pnuvax Incorporated
- Serum Institute
- Shinogi
- Shenzhen Kangtai Biological Products
- SK Bioscience
- Walvax Biotechnology
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

